No abstract

No abstract

The clinical efficacy of an oral contraceptive containing 0.150 mg desogestrel + 0.030 mg ethinylestradiol was studied by nine Scandinavian investigators in a total of 198 women and 2055 cycles. The preparation was found to be highly effective, and a low incidence of minor adverse side effects was reported. The incidence of spotting and breakthrough bleeding, though initially rather high, decreased over the first six cycles, and coincided with a high incidence of missed tablets. No serious side effects occurred, and there were few withdrawals because of complaints suspected of being attributable to the preparation.

During administration of an oral contraceptive pill containing 0.150 mg desogestrel and 0.030 mg ethinylestradiol, routine liver function tests were performed before and after 3, 6, and 12 months of treatment. No significant changes in serum amino aspartate transferase or serum alanine amino transferase were recorded during treatment. The serum alkaline phosphatase level decreased significantly after 3 and 6 months and then returned to normal. No changes in serum bilirubin were found. Briefly, no significant changes in the liver function tests were found, indicating no impairment of the liver function throughout the medication period.